Press Releases ChromaDex Corporation

Equities

CDXC

US1710774076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.44 ^USD	+1.47%		-6.78%	+140.56%

Apr. 23	Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market	CI
Apr. 09	Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe	Apr. 26	AQ
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®	Apr. 25	BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market	Apr. 24	AQ
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024	Apr. 24	BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market	Apr. 23	BU
ChromaDex Announces Tru Niagen is Now Third-Party Verified through the Alkemist Assured Transparency Program	Mar. 27	AQ
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program	Mar. 26	BU
ChromaDex : March 2024 Investor Presentation	Mar. 18	PU
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results	Mar. 06	BU
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024	Feb. 21	BU
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024	Feb. 06	AQ
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024	Feb. 05	BU
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference	Jan. 26	BU
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen	Dec. 21	AQ
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®	Dec. 20	BU
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)	Nov. 30	BU
ChromaDex - Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia Patients	Nov. 16	AQ
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients	Nov. 15	BU
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023	Nov. 09	BU
ChromaDex Corporation Reports Third Quarter 2023 Financial Results	Nov. 08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ChromaDex Corporation

Equities

CDXC

US1710774076

Press Releases

Filters